A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

NCT00251459 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

5000

Enrollment

INDUSTRY

Sponsor class

Conditions

Choroidal Neovascularization
Age-related Macular Degeneration

Interventions

DRUG: rhuFab V2 (ranibizumab)

Sponsor

Genentech, Inc.